(4R)-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: (4R)-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1lambda6-benzothiepin-4-ol
• 英文别名: (4R)-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2H-1λ6-benzothiepin-4-ol
• 化学式: C₂₀H₃₃NO₃S
• 分子量: 367.5
• InChiKey: STZVTRILLWMIMO-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS
  申请人：Satiogen Pharmaceuticals, Inc.

  公开号：US20190247390A1

  公开（公告）日：2019-08-15

  Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
• US8680062B2
  申请人：——

  公开号：US8680062B2

  公开（公告）日：2014-03-25
• [EN] BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE<br/>[FR] INHIBITEURS DU RECYCLAGE DE L'ACIDE BILIAIRE POUR LE TRAITEMENT DE L'ANGIOCHOLITE SCLÉROSANTE PRIMAIRE ET DE LA MALADIE INFLAMMATOIRE DE L'INTESTIN
  申请人：LUMENA PHARMACEUTICALS INC

  公开号：WO2014144650A2

  公开（公告）日：2014-09-18

  Provided herein are methods of treating or ameliorating primary sclerosing cholangitis and inflammatory bowel disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating primary sclerosing cholangitis comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
• [EN] METHODS FOR TREATING CHOLESTASIS<br/>[FR] PROCÉDÉS DE TRAITEMENT DE LA CHOLESTASE
  申请人：MIRUM PHARMACEUTICALS INC

  公开号：WO2020167958A1

  公开（公告）日：2020-08-20

  Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.